Polfarmex
Polfarmex is a privately-held Polish generic pharmaceutical manufacturer founded in 1989 in Kutno, producing prescription drugs, OTC medications, dietary supplements, and cosmetics for patients and healthcare professionals across Poland and 15 export markets, with 700+ employees and 80% in-house R&D.
- Company typePrivate
- Founded1989
- HeadquartersKutno, Poland
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polfarmex does
Polfarmex S.A. is a privately-held Polish generic pharmaceutical manufacturer headquartered in Kutno, founded in 1989 by Mieczysław Wośko and remaining under family ownership with 100% Polish capital. The company operates from an integrated production facility at ul. Józefów 9 in Kutno and employs over 700 people, producing four product categories: prescription (Rx) medications, over-the-counter (OTC) drugs, dietary supplements, and cosmetics. Its current OTC portfolio spans respiratory (LevoDril, Atussan), sleep (Nodisen, Melatonina Polfarmex 5 mg), cold/flu (Apselan Plus), and immunostimulation (Eloprine 500 mg) indications.
The company's core technology is generic drug development and in-house manufacturing, with a stated 80% in-house R&D ratio. Polfarmex is positioning for portfolio extension into biologics (leki biologiczne) and added-value medicines (leki z wartością dodaną), and maintains a Pharmaceutical Quality System, pharmacovigilance reporting, and product responsibility programs. A total of 36 products have secured "Polish drug" (lek polski) status on the national reimbursement list, qualifying patients for a 10% price reduction and granting preferential positioning in pharmacy reimbursement.
Commercially, Polfarmex runs a hybrid go-to-market: sales-led B2B distribution through pharmaceutical wholesalers and pharmacy networks in Poland, plus export sales across 15 foreign markets via local partners/distributors; overlaid with product-led digital channels including four patient-education websites (na bezsenność.pl, bezzakazen.pl, nodisen.pl, levodril.pl), an HCP services portal mandated by Polish pharmaceutical law, and active social media on Facebook, LinkedIn, and YouTube. Direct buyers are pharmaceutical wholesalers and pharmacies; end users are patients and the healthcare professionals who prescribe or recommend the products. Revenue is not publicly disclosed, and the company has no subsidiaries, no disclosed funding rounds, and no recorded M&A activity.
Polfarmex firmographics
Firmographics- Name
- Polfarmex
- Legal name
- Polfarmex S.A.
- Website
- https://polfarmex.pl
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Polfarmex is a privately-held Polish generic pharmaceutical manufacturer founded in 1989 in Kutno, producing prescription drugs, OTC medications, dietary supplements, and cosmetics for patients and healthcare professionals across Poland and 15 export markets, with 700+ employees and 80% in-house R&D.
- Ownership category
- akta.pro rank
Polfarmex industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Polfarmex is headquartered
LocationHeadquarters
- HQ city
- Kutno
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Polfarmex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Prescription Drugs (Rx): Revenue from prescription-only medications, including products with Polish drug status offering 10% price reduction for patients
- Over-the-Counter Drugs (OTC): Revenue from non-prescription medications including products like Apselan Plus, LevoDril, Nodisen, Melatonina, Eloprine, Atussan
- Dietary Supplements: Revenue from dietary supplement products
- Cosmetics: Revenue from cosmetic products under product category
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Polfarmex product offering
Product offeringCore offering
Polfarmex develops and manufactures generic pharmaceutical products, including prescription drugs (Rx), over-the-counter medications (OTC), dietary supplements, and cosmetics. Approximately 80% of its medications are developed in-house via its R&D operations, and it has a particular focus on added-value medicines and biologics. The company distributes its products through pharmaceutical wholesalers and pharmacy networks, primarily within Poland but also across 15 foreign markets.
Product overview
Polfarmex S.A. is a Polish generic pharmaceutical manufacturer with 35+ years of market presence. The company operates as a 100% Polish capital entity with over 700 employees. Their product portfolio includes prescription medications (leki na receptę), over-the-counter medications (leki bez recepty), dietary supplements (suplementy diety), and cosmetics (kosmetyki). The company emphasizes that 80% of their medications come from in-house development. Their OTC products include antitussives (LevoDril, Atussan), sleep aids (Nodisen, Melatonina Polfarmex), cold/flu remedies (Apselan Plus), and immunostimulants (Eloprine). The company serves 15 foreign markets and maintains dedicated patient and professional services portals.
Differentiator
Problem solved
Functional benefit
Products and services
- Prescription (Rx) Generic Pharmaceuticals Generic prescription-only medications manufactured by Polfarmex, including products holding "Polish drug" status that qualify patients for a 10% price reduction. Sold through pharmacy networks across Poland and 15 foreign markets for dispensing to patients with relevant prescriptions.
- Over-the-Counter (OTC) Medications Over-the-counter medications for the treatment of respiratory conditions, cough, sleep disorders, infections, and cold/flu symptoms, sold to consumers through pharmacies without prescription. Includes Apselan Plus (ibuprofen + pseudoephedrine), LevoDril (levodropropizine syrup), Atussan (butamirate citrate syrup), Melatonina Polfarmex (5 mg melatonin tablets), Nodisen (diphenhydramine 50 mg tablets), and Eloprine (inosine pranobex 500 mg tablets).
- Dietary Supplements Polfarmex-branded dietary supplements sold to consumers, including sleep and general-health formulations, distributed through pharmacy networks.
- Cosmetics Polfarmex-branded cosmetic products sold through pharmacy distribution channels, forming part of the company's broader consumer-health portfolio alongside Rx, OTC, and supplements.
- Apselan Plus Over-the-counter coated tablet containing ibuprofen 200 mg and pseudoephedrine hydrochloride 30 mg, used to relieve cold and flu symptoms in adult consumers.
- LevoDril 60mg/10ml Syrup Over-the-counter antitussive syrup containing levodropropizine 60 mg/10 ml, used for the relief of dry cough.
- Melatonina Polfarmex 5mg Over-the-counter melatonin 5 mg tablets used for sleep regulation and treatment of sleep disorders.
- Nodisen 50mg Over-the-counter antihistamine tablet containing diphenhydramine hydrochloride 50 mg, used as a sleep aid and for short-term treatment of insomnia.
- Atussan Syrup 1.5 mg/ml Over-the-counter antitussive syrup containing butamirate citrate 1.5 mg/ml, used for cough treatment and supplied in 150 ml bottles.
- Eloprine 500 mg Over-the-counter immunostimulant tablet containing inosine pranobex 500 mg, used in the treatment of viral infections, supplied in packs of 50 tablets.
Quantifiable outcome
- 36 products received 'Polish drug' status providing patients with 10% price reduction
- +2 more outcomes
Companies that use Polfarmex
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Polfarmex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature2 records
Polfarmex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- PZU Życie S.A.minorPZU Życie S.A. provided funding from their prevention fund to Polfarmex for training 120 employees as fire evacuation coordinators in the production facility. This demonstrates the company's commitment to employee safety through external partnerships.
- Wośko Family Foundation (Fundacja Rodziny Wośko)coreThe Wośko Family Foundation operates as Polfarmex's corporate social responsibility arm, located in Siemienice, Krzyżanów. The foundation handles CSR activities and scholarship programs, demonstrating the company's commitment to social responsibility and community engagement.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Polfarmex competitors and assessment
Company assessmentDirect peers
- Polpharma: Largest Polish pharmaceutical manufacturer and Polfarmex's most direct domestic counterpart, producing generic Rx/OTC medicines in Poland with in-house R&D and international exports — closely comparable on geography, product mix, and business model.
- KRKA: Slovenian generic pharmaceutical manufacturer with strong Central/Eastern European presence and vertical integration across APIs to finished dosage forms — analogous scale, R&D depth, and export footprint to Polfarmex.
- Gedeon Richter: Hungarian-headquartered pharma group with a major generics franchise across Europe and select biosimilar/biological ambitions — comparable generic manufacturing base and CEE-centric international footprint.
- Zentiva: Central European generic and OTC pharmaceutical manufacturer headquartered in Prague with broad European distribution — comparable business model targeting generic Rx/OTC across multiple European markets.
- Tarchomińskie Zakłady Farmaceutyczne "Polfa": Historic Polish pharmaceutical manufacturer producing generic and OTC medicines domestically and abroad — directly comparable Polish-headquartered generic competitor with similar therapeutic breadth.
- Egis Pharmaceuticals: Hungarian generic and specialty pharmaceutical manufacturer (Servier group) with a CEE-focused export model and in-house R&D — closely comparable in scale, geographic orientation, and product mix.
Broad incumbents
- STADA Arzneimittel: Large European-focused generics and consumer health company operating across most European markets — overlaps Polfarmex on generic Rx/OTC and consumer health but at materially greater scale.
- Sandoz Group: Novartis-spinout global generics and biosimilars leader, supplying European and global markets — directly competes on generic small molecules where Polfarmex participates.
- Viatris: Global off-patent branded and generics manufacturer with strong European footprint through the Mylan heritage — competes head-to-head on many generic molecules Polfarmex produces.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad portfolio across prescription generics, OTC, and biosimilars — competes with Polfarmex on many of the same molecules but at global scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Polfarmex social profiles
Digital presencePolfarmex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polfarmex leadership team
Management profileNumber of profiles
Profiles1 record
Polfarmex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polfarmex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polfarmex
What does Polfarmex do?
Polfarmex develops and manufactures generic pharmaceutical products, including prescription drugs (Rx), over-the-counter medications (OTC), dietary supplements, and cosmetics. Approximately 80% of its medications are developed in-house via its R&D operations, and it has a particular focus on added-value medicines and biologics. The company distributes its products through pharmaceutical wholesalers and pharmacy networks, primarily within Poland but also across 15 foreign markets.
Is Polfarmex a public or private company?
Polfarmex is a private company. It is classified as family owned and is currently operating.
When was Polfarmex founded?
Polfarmex was founded in 1989. It employs 501 to 1,000 people.
Where is Polfarmex based?
Polfarmex is headquartered in Kutno, Poland, in the Europe region.
How does Polfarmex make money?
Four revenue lines are on record. Prescription Drugs (Rx) is the primary driver. The others are over-the-Counter Drugs (OTC), dietary Supplements and cosmetics.
Who are Polfarmex's main competitors?
Direct peers on record are Polpharma, KRKA, Gedeon Richter, Zentiva, Tarchomińskie Zakłady Farmaceutyczne "Polfa" and Egis Pharmaceuticals. Broad incumbents are STADA Arzneimittel, Sandoz Group, Viatris and Teva Pharmaceutical Industries.
Does Polfarmex have an API?
No public API is recorded for Polfarmex.
What industry is Polfarmex in?
Polfarmex's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.